Zai Lab Limited (HKG:9688)
19.80
+0.94 (4.98%)
Oct 21, 2026, 3:59 PM HKT
Zai Lab Revenue
Zai Lab had revenue of $106.31M USD in the quarter ending June 30, 2026, a decrease of -3.33%. This brings the company's total for the last twelve months to $449.61M, up 5.10% year-over-year. In the year 2025, Zai Lab had annual revenue of $460.16M with 15.33% growth. That makes Zai Lab the 11,819th largest company in the world by revenue and 709th in Hong Kong.
Revenue (ttm)
$449.61M
Revenue Growth
+5.10%
P/S Ratio
6.27
Revenue / Employee
$252.03K
Employees
1,784
Market Cap
23.20B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 460.16M | 61.17M | 15.33% |
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | 129.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| 3SBio | 20.63B |
| Shanghai Henlius Biotech | 8.58B |
| Shanghai Junshi Biosciences | 3.49B |
| InnoCare Pharma | 3.21B |
| Everest Medicines | 2.78B |
| Biocytogen Pharmaceuticals (Beijing) | 1.96B |
| InSilico Medicine Cayman TopCo | 1.06B |
| Duality Biotherapeutics | 972.22M |
Zai Lab News
- 4 days ago - Zai Lab management to meet with Cantor - TheFly
- 6 days ago - Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases - Business Wire
- 21 days ago - Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - Business Wire
- 7 weeks ago - Zai Lab price target raised to $36 from $27 at JPMorgan - TheFly
- 7 weeks ago - Z.ai shares surge 8% after releasing new AI model running only on Chinese chips - CNBC
- 1 month ago - Zai Lab (ZLAB) CFO Yajing Chen Sells 260 Shares, Insider Selling Trend Persists - GuruFocus
- 2 months ago - Zai Lab and Argenx announce results from Alkivia Phase 3 study - TheFly
- 2 months ago - Zai Lab and Argenx announce results from Alkivia Phase 3 study - TheFly